* High-risk conditions include chronic pulmonary, cardiovascular, renal, hepatic, hematologic, or metabolic disorders; immunosuppression; cognitive dysfunction; spinal cord injuries; seizure disorders; and other neuromuscular disorders.
State-Specific Influenza Vaccination Coverage Among AdultsUnited States, 2006-07 Influenza Season
Adult groups included in the 2008 Advisory Committee on Immunization Practices (ACIP) recommendation (1) for annual influenza vaccination include all persons aged >50 years, women who will be pregnant during the influenza season, persons aged 18-49 years with high-risk conditions,* and other persons at increased risk for complications from influenza. Health-care personnel and household contacts and caregivers of persons at high risk also should receive annual influenza vaccination, as should adults who want to reduce their risk for becoming ill with influenza or for transmitting it to others. Healthy People 2010 influenza vaccination coverage targets are 90% among all persons aged >65 years and 60% among persons aged 18-64 years who have one or more high-risk conditions (2) . Data from the 2006 and 2007 Behavioral Risk Factor Surveillance System (BRFSS) surveys indicate that influenza vaccination coverage among adults for the 2006-07 season increased significantly compared with the 2005-06 season, reaching 35.1% among persons aged 18-49 years with high-risk conditions, 42.0% among all persons aged 50-64 years, and 72.1% among all persons aged >65 years. However, vaccination coverage remained well below Healthy People 2010 targets. Increasing influenza vaccination coverage among adults in the United States will require more cooperation among health-care providers, professional organizations, vaccine manufacturers, and public health departments to raise public awareness about influenza vaccination and to ensure continued distribution and administration of available vaccine throughout the vaccination season.
BRFSS is an ongoing, annual state-based telephone survey that collects information from approximately 400,000 randomly selected noninstitutionalized U.S. civilian adults aged >18 years on health risk behaviors, preventive health practices, and health-care use. Data are collected monthly in all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and Guam, and weighted by age, sex, and race/ethnicity to reflect each area's adult population. To determine influenza vaccination coverage, respondents were asked, "During the past 12 months, have you had a flu shot?" and "During the past 12 months, have you had a flu vaccine that was sprayed in your nose?" Each year, BRFSS also solicits information regarding identified high-risk conditions; influenza-related high-risk conditions in the 2006 and 2007 surveys were diabetes, asthma, myocardial infarction, and coronary heart disease. To better approximate vaccination coverage, analysis was restricted to respondents interviewed during February-August of each survey year, thereby excluding vaccinations received during previous and subsequent seasons. The median state response ±2.3) for non-Hispanic blacks, 39.5% (CI = ±8.4) for Asians, 43.6% (CI = ±6.8) for American Indians/Alaska Natives, and 34.0% (CI = ±3.4) for Hispanics. Among states and areas, the median percentage-point difference in vaccination coverage from 2005-06 to 2006-07 among persons aged 50-64 years with identified high-risk conditions was 4.8 (range: -11.4 to 18.4) and among those without these conditions was 4.9 (range: -3.8 to 10.8) ( Table 2) . Among adults aged >65 years, influenza vaccination coverage was 72.1% for the 2006-07 season, ranging from 60.8% (Nevada) to 81.0% (Rhode Island) (median: 73.3%) ( Table 1) . Coverage was significantly higher for non-Hispanic whites (74.2%) compared with other racial/ethnic groups (63.2%) as a whole. Coverage was 57.1% (CI = ±2.9) for non-Hispanic blacks, 83.3% (CI = ±8.8) for Asians, 63.1% (CI = ±7. 4 increased to levels nearly equal to those achieved before the shortage. However, the coverage rebound for persons aged 50-64 years without high-risk conditions was weaker than for other groups. Targeted communications efforts might be appropriate for persons in this population group who might believe they are not recommended for vaccination (and their health-care providers). The gap in vaccination coverage between whites and other racial/ethnic groups remained essentially the same for the 2005-06 and 2006-07 seasons, except for Asians, for whom the racial/ethnic gap was eliminated. Veterans Administration clinics also eliminated racial/ethnic disparities in influenza vaccination among older adults by using multimodal programs. These include standing orders, patient reminders, freestanding vaccination clinics, assessment of vaccination rates with feedback, and incentives to clinicians to improve influenza vaccination coverage (5) .
NHIS results for the two most recent influenza seasons indicate that approximately 84% of all influenza vaccinations were administered during September-November (6). Health-care providers, health departments, and community vaccinators should offer influenza vaccine routinely as soon as it is available and throughout the entire influenza season.
CDC compared the results with estimates from the 2007 National Health Interview Survey (NHIS). NHIS is a national household survey conducted annually with a face-to-face interview method. Estimated influenza vaccination coverage from the 2007 NHIS was lower than that from BRFSS for all age groups examined (i.e., 25.5% among persons aged 18-49 years with high-risk conditions, 36.0% among persons aged 50-64 years, and 65.6% among persons aged >65 years) (1).
The NHIS estimates, all lower than the BRFSS estimates in this report, might reflect the fact that BRFSS is limited to landline telephones. NHIS data indicate that persons with landline telephones have higher influenza vaccination rates than persons living in households without landline telephones (1,7). The findings in this report are subject to at least three other limitations. First, self-reported influenza vaccination status is subject to recall bias. Second, persons with certain highrisk conditions (e.g., emphysema, bronchitis, cancer, kidney diseases, and neurologic conditions that impair lung function) identified by ACIP were not ascertained by the survey. Finally, sample sizes for blacks and Hispanics were relatively small, which limited comparisons by age and racial/ethnic groups at state levels.
To further increase influenza vaccination coverage among all adults, health-care providers should recommend influenza vaccination in accordance with ACIP recommendations throughout the influenza season. Standing orders for vaccination should be implemented in various settings, and reminder and recall systems for patients and providers should be incorporated into medical practices and facilities that routinely provide vaccinations to adults (8) (9) (10) .
Influenza Vaccination Coverage
Among Children Aged 6-23 Months -United States, 2006-07
Influenza Season
Children aged <5 years have more influenza-related medicalcare visits compared with older children, and those aged <2 years are at the greatest risk for influenza-related hospitalizations (1) . In 2002, the Advisory Committee on Immunization Practices (ACIP) encouraged annual influenza vaccination of children aged 6-23 months and then, in 2004, recommended vaccination for this group (2) . Two doses, spaced at least 4 weeks apart, are recommended to fully vaccinate children aged <9 years who are receiving influenza vaccination for the first time. This report, based on data from the 2007 National Immunization Survey (NIS), provides an assessment of influenza vaccination coverage among children aged 6-23 months during September-December of the 2006-07 influenza season. Nationally, 31.8% of children received 1 or more doses of influenza vaccine, and 21.3% were fully vaccinated, with substantial variability among states. The findings underscore the need to increase interest in and access to influenza vaccination for more children in the United States. Further study is needed to identify knowledge deficits or logistical barriers that might contribute to continued low influenza vaccination coverage among young children. (3) . Season-to-season comparisons of influenza vaccination coverage were conducted using t-tests, with p<0.05 indicating statistical significance.
The household survey response rate was 64.9%. Providerreported vaccination records were obtained for 17,017 children aged 19-35 months, representing 68.6% of all children with completed household interviews. Of these 17,017 children, 9,710 met the age criteria for this assessment. Of these 9,710, 31.8% received 1 or more doses of influenza vaccine, and 21.3% were fully vaccinated (Table) . Nationally, no statistically significant increase was observed in either influenza coverage measure, compared with the previous season (2005-06) (4) (Figure 1 ). Nearly one third (33.1%) of children who received at least 1 dose during the 2006-07 season required, but did not receive, a second dose by January 31 (or date of interview, if interviewed in January).
Substantial variability in influenza vaccination coverage was observed among states and local areas. Among states, percentages of children who were fully vaccinated ranged from 8.6% in Mississippi to 47.6% in Rhode Island (Table) . Among the 14 local areas, these percentages ranged from 6.4% in El Paso County, Texas, to 32.8% in Alameda County, California. In the majority of states, no statistically significant increase was observed in the percentage of children who were fully vaccinated, compared with the previous season (Table) .
The first (or only) influenza vaccine dose was most often administered in weeks 43-46 (i.e., October 22-November 18) or in week 48 (i.e., November 26-December 2), with a drop in doses administered during week 47 (i.e., the period coinciding with the Thanksgiving holiday) (Figure 2 ). Among children requiring 2 doses (i.e., those with no previous dose), the second dose was most often administered in weeks 48-50 (i.e., November 26-December 10). Editorial Note: The findings in this report indicate that, during the 2006-07 influenza season, the third season since ACIP issued its recommendation for annual influenza vaccination for all children aged 6-23 months, only one in five children aged 6-23 months were fully vaccinated. Prevention of influenza and its complications among infants and young children is a public health priority because they are at greater risk for influenza complications, compared with older children. Vaccination coverage for other newly recommended infant vaccines has reached approximately 75% within 7 years of introduction (5). However, influenza vaccination coverage for children aged 6-23 months has remained low, suggesting the possible influence of factors unique to influenza vaccination, including 1) the need for annual vaccination and difficulties in scheduling annual vaccination for this large cohort of children, 2) characteristics of vaccine distribution systems at the local level (e.g., uncertainties about when and how vaccine will be delivered) leading to an inability to reliably schedule vaccination clinics, and 3) a lack of parental or provider confidence or interest in influenza prevention through vaccination. Additional studies are needed to identify barriers to improving vaccination coverage among young children. Little is known about how parental and provider concerns about influenza vaccine effectiveness or safety, or the lack of understanding of the rationale for influenza vaccination recommendations, might contribute to low coverage.
Because low vaccination coverage might be attributed, in part, to the narrow time window for influenza vaccination, ACIP has recommended that 1) providers begin to offer influenza vaccination as soon as vaccine becomes available and, if possible, by early October, and 2) vaccination efforts continue throughout the influenza season (1). These recommendations are especially important for children who require 2 doses of vaccine and for other persons who remain unvaccinated after November. Peak influenza activity has occurred in January or later in >80% of influenza seasons since 1976; in >60% of seasons, the peak was in February or later (1) . To promote influenza vaccination through November, December, and beyond, CDC created an annual National Influenza Vaccination Week, which was first observed during November 27-December 3, 2006 (6). For the current influenza season, National Influenza Vaccination Week is planned for the week of December 8-14, 2008.*
The limitations of vaccination coverage data obtained through the NIS have been discussed in previous reports (3, 5) . The findings in this report are subject to at least two additional limitations. First, because NIS interviews were conducted during the influenza season and some children might have received influenza vaccinations after the interview, vaccination coverage likely is underestimated. However, according to National Health Interview Survey data from two recent influenza seasons, approximately 85% of influenza vaccinations among all age groups were administered during September-November (1). Second, coverage estimates might be higher among children included in the NIS, compared with all children who were in the 6-23 month age group at some point during September-December. Groups of children who aged into or out of the 6-23 month cohort (and thus were excluded from the analysis) might be less likely to have been vaccinated because children aged <5 months are not recom- mended for vaccination and children aged 24-59 months have lower influenza vaccination coverage (1). The continuing low influenza vaccination coverage described in this report underscores the need to identify innovative strategies for increasing influenza vaccination coverage among young children. Health-care providers can play several key roles in efforts to increase influenza vaccination. For example, they can routinely inform parents about the substantial burden of influenza illness among young children and the benefits and safety of preventing influenza with vaccination. Additionally, they can use strategies shown to be successful at reducing missed opportunities for vaccination, including standing orders to offer vaccine to all patients throughout the influenza season, vaccination-only clinics, and reminder/recall systems (7, 8) .
Beginning with the 2008-09 influenza season, ACIP has expanded its recommendation for universal influenza vaccination to include all children aged 5-18 years, in addition to those aged 6-59 months, for whom vaccination was recommended previously (1) . Vaccination providers and programs should continue to focus vaccination efforts on fully vaccinating children and adolescents at greater risk for influenza complications (including children aged 6-23 months, who are at the greatest risk for influenza-related hospitalizations) as they transition to routinely vaccinating all children and adolescents (1). 
Influenza Vaccination Coverage Among Children Aged 6-59 Months -Eight Immunization Information System Sentinel Sites, United States, 2007-08 Influenza Season
Vaccination is the most effective way to prevent influenzaassociated morbidity and mortality (1). However, influenza vaccination coverage among children historically has been low (2,3). The Advisory Committee on Immunization Practices (ACIP) recommends annual vaccination with influenza vaccine for all children aged 6-59 months (4) . Previously unvaccinated children and children who received only 1 vaccine dose for the first time in the previous influenza season are recommended to receive 2 influenza vaccine doses (4). To assess vaccination coverage among children aged 6-59 months during the 2007-08 influenza season, CDC analyzed data from the eight immunization information system (IIS) sentinel sites.* For the eight sites, an average (unweighted) of 40.8% of children aged 6-23 months received 1 or more influenza vaccine doses, and an average of 22.1% were fully vaccinated. Among children aged 24-59 months, an average of 22.2% received 1 or more doses, and an average of 16.5% were fully vaccinated. These results indicate that influenza vaccination coverage among children remains low (2,3) and highlight the need to identify additional barriers to influenza vaccination and to develop * Among all age-eligible children (N = 9,710). † Among the subset of age-eligible children who had no influenza dose before September 1 and thus were recommended to receive 2 doses (n = 6,869). more effective interventions to promote vaccination of children aged 6-59 months who are at high risk for influenza-related morbidity and mortality (1) . IISs are useful sources to assess influenza vaccination coverage because data 1) reflect the most recent influenza season, 2) are provider-verified, and 3) can track vaccination patterns throughout the entire influenza season (September-March). For the 2008-2012 Sentinel Site Project period, CDC awarded supplemental funds to eight IISs that met the following criteria: 1) >75% of child vaccine provider sites were enrolled in the IIS, 2) >85% of children aged <6 years who resided in the sentinel site region had two or more vaccinations recorded in the IIS, and 3) >70% of doses administered were reported to the IIS within 30 days of vaccine administration. Sentinel sites in Arizona, Colorado, Michigan, Minnesota, Oregon, and Wisconsin consisted of contiguous geographic counties, postal codes, or census tracts; the other two sentinel sites consisted of the entire state of North Dakota and all New York City boroughs. As of March 31, 2008, the sum of the number of children aged 6-23 months and 24-59 months who were enrolled in the IIS at the sentinel sites ranged from 7,476 in Colorado to 535,877 in New York City.
To reflect ACIP recommendations in the 2007-08 influenza season (4), full vaccination was defined as 1) receipt of 2 valid influenza vaccine doses in the current season among influenza vaccine naive children and children who received 1 dose for the first time during September 1, 2006-March 31, 2007, or 2) receipt of 1 vaccine dose in the current season among all other children (4) . This definition of full vaccination represented a change from previous influenza seasons, in which children who received only 1 dose in their first year of vaccination were recommended to receive 1 dose in the subsequent season (4). In accordance with ACIP recommendations, doses were considered valid if they were separated by at least 4 weeks.
The numbers of children aged 6-23 months or 24-59 months who resided in the sentinel site area and were enrolled in the IIS were the denominators for calculating vaccination coverage at each of the eight sites. The average for the eight sites was calculated by summing the percentages of children vaccinated at each sentinel site and dividing by the total number of sites (eight). Analyses included only children aged 6-23 months or 24-59 months during the entire influenza season to ensure that all children in the study had the same opportunity for vaccination. To determine the weekly pattern of vaccination, at each of the eight sites the number of weekly influenza vaccine doses administered to children aged 6-59 months during the 2007-08 influenza season was determined and converted into a percentage of all doses administered during the entire season; then those eight percentages were averaged.
During the 2007-08 influenza season, the average coverage with one or more vaccine doses among children aged 6-23 months was 40.8% (range among the eight sites: 25.2%-55.6%); 22.1% (range: 12.4%-32.8%) were fully vaccinated ( Figure 1) . Among children aged 24-59 months, the average coverage was 22.2% (range: 11.6%-33.9%) for 1 or more vaccine doses; 16.5% (range: 6.6%-27.2%) were fully vaccinated ( Figure 2) . Three of the eight sentinel sites (Arizona, Michigan, and Oregon) had reported vaccination coverage data for previous influenza seasons. Minor modifications had been made to these sentinel site geographic areas from the 2006-07 season to the 2007-08 season, making direct comparisons difficult. However, at each of the three sites, the percentage of children receiving 1 or more doses did not change substantially for children aged 6-23 months: Arizona, from 30.4% in 2006-07 to 32.2% in 2007-08; Michigan, from 38.8% to 42.1%; and Oregon, from 46.6% to 42.4%. Coverage with 1 or more doses also did not change substantially for children aged 24-59 months: Arizona, from 15.7% to 14.5%; Michigan, from 19.3% to 21.9%; and Oregon, from 22.4% to 22.8% (2) .
The average percentage of influenza vaccine doses administered to children aged 6-23 months and 24-59 months across the eight sites increased steadily during age, including the need to vaccinate each year, the short time period in which to deliver vaccine, limited awareness of the magnitude of influenza burden in young children (5), and the need for 2 doses in the first or second year of vaccination to effectively prevent influenza-related illnesses (6,7). Additional effective educational and programmatic interventions that address these barriers, and studies that identify other barriers to influenza vaccination among parents and vaccine providers, are needed. ACIP recommends that health-care providers offer influenza vaccination to all eligible children who visit for other reasons during the entire influenza season (1). More visits to vaccine providers are required for children aged 6-23 months to meet ACIP vaccination recommendations, compared with children aged 24-59 months; the higher influenza vaccination coverage in the younger age group might have been influenced by more frequent visits to vaccine providers for other reasons. Boosting influenza vaccination coverage will require more parents to be aware of, and act on, the need to schedule visits to providers specifically for influenza vaccination.
Emphasizing the benefits of vaccination throughout the influenza season, including in December and beyond, has been advocated as a way to help improve vaccination coverage (1). Campaigns such as National Influenza Vaccination Week † aim to raise awareness about the need for influenza vaccination and to increase vaccination use later in the season. At the IIS sentinel sites during the 2007-08 influenza season, limited vaccination was observed in December and later months. Additionally, across the eight sites, at least 60% Peak week of influenza activity dren aged 6-23 months and 24-59 months, <18% and <13% of doses, respectively, were administered during January-March 2008. By week, the greatest average percentages (8.8%-9.1%) of children aged 6-23 months who were partially vaccinated (i.e., required 2 doses but received only 1 dose) received their only dose during November 3-16 or November 24-30. The greatest average weekly percentages (9.2%-10.6%) of partially vaccinated children aged 24-59 months received their single dose during October 20-November 16. Editorial Note: These data from the eight sentinel sites reflect the first report of vaccination coverage among children during the 2007-08 influenza season. Four influenza seasons after ACIP recommended annual vaccination for children aged 6-23 months, vaccination coverage in this age group remains low. Coverage at these eight sites was even lower among children aged 24-59 months, two influenza seasons after the ACIP recommended annual vaccination for that age group. Among the three sentinel sites that reported influenza vaccination coverage in previous seasons, no substantial increase in vaccination coverage was observed for the 2007-08 season (2) .
Administration of influenza vaccine is subject to several challenges that might contribute to low vaccination cover-of partially vaccinated children aged 6-23 months and 24-59 months received their only dose of vaccine before December, indicating that sufficient time remained to administer the second dose before the end of the influenza season. Vaccine providers and immunization programs can support parent awareness by sending reminder notices. Continued efforts to encourage providers to offer influenza vaccine and to encourage parents to seek vaccination, throughout the influenza season are needed (1) .
The findings in this report are subject to at least two limitations. First, although the IIS sentinel sites have >75% vaccine provider site participation, not all provider sites in all sentinel sites are enrolled in the IIS. Lacking information on vaccines administered by nonenrolled traditional health-care providers and nontraditional providers (e.g., pharmacists) might have resulted in underestimates of vaccination coverage. Second, these results might not be generalizable to the entire U.S. population and should be viewed as representative of their specific geographic areas only.
Protecting young children against influenza and its complications is an important public health goal. Implementation of provider-based strategies shown to be effective in increasing childhood coverage with other vaccines (e.g., reminder notices and extended clinic hours) (8) are particularly important for influenza vaccination, given the limited period during which vaccination occurs. However, specific parent-based and provider-based strategies that address the challenges associated with influenza vaccination also need to be identified, especially as vaccination recommendations expand to include all children aged >6 months during the 2008-09 influenza season (1). Children and adolescents at greater risk for influenza complications, including those aged 6-59 months, should continue to be a focus of vaccination efforts as providers and programs transition to routine influenza vaccination of youths aged >6 months (1).
Influenza ActivityUnited States and Worldwide, May 18-September 19, 2008
During May 18-September 19, 2008, influenza A (H1), influenza A (H3), and influenza B viruses were detected worldwide and were identified sporadically in the United States. This report summarizes influenza activity in the United States and worldwide since the last update (1) 
United States
In the United States, CDC uses 10 different systems for national influenza surveillance (2) . Seven of these systems are operated year-round and provided data for this report.* During May 18-September 19, 2008, World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System collaborating laboratories in the United States tested 19,774 specimens collected from the United States for influenza viruses; 147 (<1%) were positive. Of these, 81 (55%) were influenza A viruses, and 66 (45%) were influenza B viruses. Of the influenza A viruses, five (6%) were influenza A (H1) viruses, 17 (21%) were influenza A (H3) viruses, and 59 (73%) were not subtyped. Twenty-two states, representing the nine public health surveillance regions, reported influenza viruses. Among positive tests, 66% were reported from Hawaii and Florida: 43 (29%) from Hawaii and 54 (37%) from Florida. The majority of the viruses were reported during late May through July. Only 28 viruses (20 influenza A and eight influenza B viruses) were reported in August and early September. During May 18-September 19, 2008, the weekly percentage of visits to U.S. sentinel providers for influenza-like illness remained below the national baseline of 2.2% (range: 0.5%-0.9%) according to data from the U.S. Influenza Sentinel Provider Surveillance Network. The weekly percentage of visits for acute respiratory illness to sentinel providers from the BioSense Surveillance System also remained below the national baseline of 3.2% (range: 1.3%-1.8%).
Data from the 122 Cities Mortality Reporting System indicate that the percentage of deaths attributed to pneumonia and influenza was below the epidemic threshold throughout the summer. A total of 86 influenza-associated deaths were reported during the 2007-08 influenza season; only one of these deaths occurred since May 18, 2008. No human cases of novel influenza A have been reported to the National Notifiable Diseases Surveillance System during the summer months.
Worldwide
During May 18-September 19, 2008, influenza A (H1), influenza A (H3), and influenza B viruses were detected worldwide. In Africa, influenza A (H1) viruses predominated. In Asia, influenza A (H1), A (H3), and B viruses were detected, and the predominant virus subtype varied by country. In South America, influenza A (H1) and influenza B viruses were detected. In North America, Europe, and Oceania, influenza A (H1), A (H3), and B viruses were detected sporadically.
Antigenic Characterization of Influenza Virus Isolates
The 
Resistance Profiles of Influenza Virus Isolates
During the 2007-08 influenza season (September 30, 2007-May 17, 2008), the prevalence of oseltamivir-resistant influenza A (H1N1) viruses was 10.9%; no resistance to oseltamivir was detected among influenza A (H3N2) or influenza B viruses during that season (1). During May 18-September 19, 2008, the WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza at CDC, a member of the WHO Global Influenza Surveillance Network, received 187 isolates that were collected during this period and analyzed them for neuraminidase resistance. Of these isolates, 185 were sensitive to zanamivir, and two required additional testing. Of the 86 influenza A (H1N1) viruses received from 14 countries and analyzed for oseltamivir resistance, 40 (46.5%) were resistant. Only five of the influenza A (H1N1) viruses that were analyzed were from the United States; two of these viruses were resistant to oseltamivir. None of the 27 influenza A (H3) viruses analyzed for neuraminidase resistance were resistant to oseltamivir. Editorial Note: During May 18-September 19, 2008, influenza A (H1), influenza A (H3), and influenza B viruses were detected worldwide. The influenza virus type and subtype that will predominate, the severity of influenza-related disease activity, and the level of antiviral resistance during the 2008-09 influenza season cannot be forecast in advance of the influenza season. However, of the isolates submitted for antigenic characterization during May through early September from Northern and Southern Hemisphere countries, the majority were antigenically similar to the viruses contained in the 2008-09 influenza vaccine for the Northern Hemisphere.
Human Infections with Avian Influenza A (H5N1) Viruses
Annual influenza vaccination remains the best method for preventing influenza and its potentially severe complications. When vaccine strains are well matched to influenza viruses circulating during the influenza season, vaccine effectiveness typically exceeds 50% and can be as high as 70%-90% in healthy adults. Data from an interim within-season vaccine effectiveness study during the 2007-08 influenza season showed that overall vaccine effectiveness for prevention of medically attended, laboratory-confirmed influenza infection was 44%, despite a suboptimal match between two of the three vaccine strains and the predominant circulating strain (3). Vaccine effectiveness against influenza A (H3N2), the subtype most frequently associated with increases in influenza-related complications and deaths, was 58% (3). These data demonstrate that influenza vaccination can offer substantial benefit, even in years where the match between circulating strains and vaccine strains is suboptimal.
The Advisory Committee on Immunization Practices (ACIP) recently expanded its recommendations for influenza vaccination to include all persons aged 6 months-18 years. Vaccine providers should begin vaccinating all persons in this population during the 2008-09 influenza season, if feasible, but this recommendation should be fully implemented no later than the 2009-10 influenza season (5) . In addition, vaccination efforts should continue to be targeted toward persons who are at increased risk for influenza complications, including 1) children aged 6 months-4 years, 2) adults aged >50 years, 3) children and adults of any age who are immunosuppressed or have other chronic medical conditions that might predispose them to influenza-related complications, 4) persons who reside in nursing homes or chronic care facilities, or 5) females who will be pregnant during the influenza season (4). Household and other close contacts of persons at greater risk for influenza infection, including health-care workers and contacts and outof-home caregivers for all children aged <5 years, also should be vaccinated (4) . Health-care providers should begin offering influenza vaccination as soon as vaccine becomes available and should continue vaccination efforts throughout the influenza season (4). Enhanced surveillance for oseltamivir-resistant viruses is ongoing at CDC and will continue during the 2008-09 influenza season. At this time, oseltamivir and zanamivir remain the medications recommended for treatment and chemoprophylaxis of influenza (4) . Randomized controlled clinical trials conducted before the emergence of oseltamivir-resistant influenza viruses have demonstrated that neuraminidase inhibitors such as oseltamivir and zanamivir reduce the duration and severity of illness if started within 48 hours of illness onset (6) and are approximately 80% effective in preventing illness among close contacts of patients with influenza (7). Multiple observational studies have found that treatment with oseltamivir improves outcomes associated with influenza complications among hospitalized patients with laboratory-confirmed influenza, including a reduction in mortality (8) , and hospital length of stay (9) . Clinicians providing care for patients during the influenza season, especially those requiring hospitalization for respiratory illness, should consider influenza as a possible cause of illness and evaluate the potential benefits of treating influenza with neuraminidase inhibitors. Recommendations for use of neuraminidase inhibitors might be revised as the 2008-09 influenza season progresses if surveillance data indicate an increase in the prevalence of oseltamivir-resistant influenza viruses in the United States.
Vaccination to prevent influenza is the cornerstone of prevention efforts, and influenza vaccination can prevent infection regardless of whether circulating viruses are sensitive or resistant to antiviral medications. To reduce the burden of influenza in the United States, CDC continues to recommend a three-pronged approach: 1) influenza vaccination, 2) use of neuraminidase inhibitor antiviral medications when indicated for treatment or prevention, and 3) use of other measures to decrease the spread of influenza, including promotion of hand hygiene, respiratory hygiene, cough etiquette, and staying home from work and school when ill.
Influenza surveillance reports for the United States are posted on the Internet weekly during October-May at http://www. cdc.gov/flu/weekly/fluactivity.htm. Additional information regarding influenza viruses, influenza surveillance, influenza vaccine, and avian influenza is available at http://www.cdc. gov/flu.
Progress Toward Measles Elimination -Japan, 1999-2008
In 2005, the Regional Committee of the World Health Organization (WHO) Western Pacific Region (WPR) set a target date of 2012 for measles elimination in all WPR member states. In Japan, measles control strategies have included 1) a nationwide public awareness campaign implemented in 2001 to promote timely vaccination with the first dose of measlescontaining vaccine (MCV1) administered on or after age 12 months, and 2) a 2-dose MCV schedule with the second dose (MCV2) administered at age 5-6 years, adopted in 2006 in accordance with the recommended WPR measles elimination strategy. However, during 2007-2008, Japan experienced a large measles outbreak, which resulted in exportation of measles cases from Japan into countries where measles elimination had been achieved. This report describes the epidemiology of measles in Japan during 1999-2008 and approval of a National Measles Elimination Plan in December 2007 that includes recommendations for immunization strategies, case-based measles surveillance, and monitoring to ensure elimination of measles by 2012. Measles continues to be endemic in Japan, with most cases occurring in children before school entry, except for 2007 and 2008, when a shift to an older age group was observed. With implementation of the National Measles Elimination Plan, Japan is expected to make progress toward achieving the WPR measles elimination goal.
During 1999-2007, measles surveillance in Japan consisted of aggregate case reporting from two sentinel surveillance systems: pediatric and adult. In the pediatric sentinel system, cases were reported from a representative sample of approximately 3,000 pediatric inpatient and outpatient facilities. In the adult sentinel system, cases were reported from a sample of approximately 450 inpatient hospitals. In April 2006, the adult definition was changed from age >18 years to age >15 years; however, some pediatric sentinel sites continued to report cases in persons aged >15 years. For both pediatric and adult surveillance systems, the case definition for measles was the presence of a generalized rash, fever (101.3°F [38.5°C]), and cough, coryza, or conjunctivitis; or laboratory-confirmed measles. Laboratory confirmation of cases was performed by detection of measles-specific immunoglobulin M (IgM) antibodies, which was usually performed by commercial laboratories; virus isolation and genotyping were conducted by public health institutes in the country's prefectures (i.e., Japanese jurisdictions that are larger than districts and smaller than regions). During 2000-2007, the total number of pediDuring 2000-2007, the total number of pedithe total number of pediatric measles cases was estimated using a multihypergenomic
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distribution by multiplying the average number of reported cases per sentinel medical facility by the total number of similar medical facilities nationally (1). For adult cases, estimates could not be calculated because sentinel hospitals were not chosen for representativeness. In January 2008, the two sentinel surveillance systems were replaced with nationwide case-based reporting of measles, and all health practitioners were required to report any clinical or laboratory-confirmed case to local health offi cials. Population immunity and vaccinalocal health officials. Population immunity and vaccination coverage for eight vaccine-preventable diseases in Japan were measured by the National Epidemiological Surveillance of Vaccine-Preventable Diseases, an annual, national seroepidemiologic survey conducted among a representative sample of the Japanese population (2) .
Measles In 2001, national MCV1 coverage was estimated at 83.2% in children aged 24-35 months. In 2002, after a pediatricianinitiated nationwide public awareness campaign, estimated MCV1 coverage increased to 96.4% among children in the same age group and to 97.9% in 2007 (Table) .
In 2007, a measles epidemic occurred with an estimated 18,000 cases nationally among children aged <15 years. Initially, measles cases were reported primarily from Tokyo and Saitama prefectures, but then spread throughout Japan during a 10-day holiday (Golden Week) in May 2007, affecting all 47 prefectures.
The epidemic continued in 2008 when, using the new nationwide case-based reporting system, a total of 9,631 measles cases were reported through June 22. Of these, 6,169 (64.1%) were clinical cases and 3,462 (35.9%) were laboratory confirmed. Cases were reported from all 47 prefectures but centered in the Tokyo metropolitan region, where 4,229 (43.9%) cases were reported, and in Hokkaido, with 1,344 (13.9%) cases (Figure 2 In response to the 2007 outbreak and to achieve the measles elimination goal agreed on by WPR member states, MCV2** coverage among children aged 5-6 yrs (%)
* During 1999-2007, measles surveillance in Japan was conducted via aggregate case reporting from two sentinel surveillance systems: pediatric and adult. In the pediatric sentinel system, cases were reported from a representative sample of approximately 3,000 pediatric inpatient and outpatient facilities. In the adult sentinel system, cases were reported from a sample of approximately 450 inpatient hospitals. In April 2006, the adult definition was changed from age >18 years to age >15 years. However, some pediatric facilities continued to report persons aged >15 years. † April-December only. § Per 100,000 population. ¶ Measles-containing vaccine, 1 dose. ** The second dose of measles-containing vaccine was added in 2006 the Japanese government approved a 5-year National Measles Elimination Plan in December 2007. The plan includes a 3-part strategy: 1) intensified efforts to achieve high vaccination coverage among children and young adults, including a 5-year catch-up campaign that began in April 2008, targeting cohorts aged 13 years and 18 years with measles and rubella combined vaccine (MR); 2) establishment of a nationwide case-based measles-rubella surveillance system; and 3) establishment of a National Measles Elimination Council and local measles elimination councils to provide program monitoring and oversight.
In addition to the 5-year catch-up MR campaign, education officials will review each child's vaccination status at school entry and during routine physical examinations during the school year, encouraging vaccination for those who are behind schedule and following up until children have received 2 doses of MCV. Although Japanese schools have no vaccination requirements for entry, a national advocacy and communication campaign also will be conducted to encourage timely administration of MCV1 at age 12-23 months and MCV2 at age 5-6 years, before entering primary school.
Editorial Note: The resurgence of measles in Japan in 2007 had wide-ranging effects, both domestically and internationally. Japanese residents with measles exported the virus into countries where measles elimination had been achieved, including the United States and Canada (4, 5) . Anecdotal reports also indicate that some visitors to Japan from the United States and Taiwan were infected with measles virus and developed measles upon return to their home countries. The international spread of measles virus from Japan provides a reminder that countries in regions that have eliminated measles need to maintain very high levels of vaccination coverage and high-quality surveillance to limit the spread of imported measles virus.
Virologic surveillance in Japan demonstrated a succession of genotypes since surveillance activities began there in the early 1990s. Genotypes D3 and D5 cocirculated for most of the 1990s, with genotype D5 more frequently detected in 2001 and genotype H1 during 2002-2005 (6,7). In 2006, genotype D5 apparently was reintroduced in Japan (8) and has been associated with measles cases imported from Japan into the United States (4, 5) .
Effective implementation of the immunization strategies in Japan's National Measles Elimination Plan is aimed at reaching high vaccination coverage (>95%) among persons aged <22 years and also is expected to affect older age groups through herd immunity. The overall goal is to achieve elimination of measles by 2012. Monitoring disease incidence, surveillance quality, and vaccination coverage is critical to ensure progress toward elimination.
Shifting to nationwide case-based surveillance was critical for Japan to progress toward measles elimination. Use of this system in 2008 enabled more representative reporting of adult cases, allowed for estimation of age-specific incidence, and provided information on the vaccination status of persons with reported measles. In addition to documenting the progress toward measles elimination, the nationwide surveillance system 1-19 (19) 20-49 (8) 50-99 (7) 100-499 will monitor the impact of measles elimination activities on the incidence of rubella and congenital rubella syndrome. The WHO-recommended strategies for measles elimination include high routine coverage with 2 doses of MCV, supplementary immunization activities when routine coverage is not adequate, high-quality case-based measles surveillance, and access to a high-quality measles laboratory network. By adopting these recommended strategies, member states of WPR have made substantial progress in reducing the number of measles cases and deaths. Moreover, in 2006, South Korea became the first country in WPR to declare measles elimination (9) . With Japan's renewed commitment and political and financial commitments from all WPR member states and partners, the region is progressing toward achieving the goal of measles elimination by 2012.
Notice to Readers

World Heart Day -September 28, 2008
Worldwide, approximately 17.5 million deaths are attributed to heart disease and stroke each year (1) . Controlling certain risk factors, such as high blood pressure, high cholesterol, diabetes, obesity, tobacco use, and physical inactivity, can help prevent heart disease and stroke.
In 2000, the World Heart Federation, a nongovernmental organization based in Geneva, Switzerland, created the annual World Heart Day campaign to increase public awareness of the threat of heart disease and stroke. The theme of this year's World Heart Day is "Know Your Risk!," a call to action for persons to understand their risk for cardiovascular disease. Approximately 100 member organizations will participate in the event this year. Activities will include free heart health screenings, walks, runs, jump rope sessions, fitness events, public talks, scientific forums, exhibitions, concerts, and sports tournaments to highlight the importance of a healthy lifestyle to prevent heart disease.
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